GLP-1 medications were developed to treat type 2 diabetes, but they have since migrated into mainstream weight loss culture with a speed that outpaced any serious public conversation about what they do and who they were designed for. Along with this rapid expansion has come a new term—”food noise”—used to describe the persistent mental preoccupation with food that these medications appear to quiet, and which has become one of the most compelling selling points for their use far beyond their original clinical purpose.
12.4 percent of American adults were taking GLP-1 medications specifically for weight loss by late 2025, more than double the 5.8 percent recorded in early 2024. Yet for someone with an active eating disorder, or a history of one, GLP-1 medications carry risks that go well beyond the standard side effect profile.
At ‘Ai Pono, we do not judge anyone for the decisions they make about their own medical care. We also work with people every day for whom food is not a neutral subject. We hold a strong commitment to Health at Every Size principles and weight-inclusive care, and most importantly, we do not endorse intentional weight loss.
What we believe is that people deserve accurate information, particularly when an eating disorder history is part of the picture.
How GLP-1 Medications Work and the Birth of Food Noise
GLP-1 (which stands for glucagon-like peptide-1) receptor agonists work by mimicking a hormone the body produces naturally in response to eating. They stimulate insulin release, slow the rate at which food moves through the stomach, and act on appetite-regulating centers in the brain, reducing hunger signals and, for many users, dramatically quieting what has come to be called “food noise.” That effect is what drove these medications from endocrinology offices into mainstream culture.
The term “food noise” describes the persistent mental preoccupation with food, eating, and hunger that many people experience throughout the day. People taking GLP-1 medications began reporting that this chatter went quiet in a way they had never experienced before, and that relief felt profound enough to generate enormous cultural interest in these drugs far beyond their original clinical purpose. The conversation that followed rarely asked where food noise comes from.
GLP-1 Medications and the Pathologization of Hunger
GLP-1 medications were originally approved to treat type 2 diabetes and, subsequently, to reduce cardiovascular risk in adults with established cardiovascular disease. In 2021, semaglutide received FDA approval for “chronic weight management,” a designation that effectively medicalized body size and opened the door to the cultural moment we are now living in.
When the body is underfed, whether through intentional restriction, chronic dieting, or the restrict-binge cycle, food preoccupation is a predictable physiological response. The brain, registering insufficient nutrition, turns up the volume on food-seeking signals, intensifying hunger and cravings in ways that are often mistaken for emotional eating rather than recognized as the body’s response to deprivation.
In that framing, food noise is not a malfunction. It is the body doing exactly what it is supposed to do, and silencing it pharmacologically addresses the signal without addressing what generated it. For someone with an eating disorder history, that distinction can be the difference between recovery and relapse.
Food preoccupation does not always originate in restriction, though. For some people, food noise reflects sensory-seeking behavior, as is common in ADHD, where the brain reaches toward stimulation and food is a readily available source of it. For others, rumination about food functions more like intrusive thinking, driven by anxiety rather than hunger. What these experiences share is that they are telling you something about unmet needs.
A medication that quiets those signals does not resolve what generated them. Approaching food noise holistically means asking what the noise is actually communicating, whether that is a need for more nourishment, sensory input, anxiety treatment, or something else entirely, and addressing that rather than suppressing the signal.
Potential Side Effects of GLP-1 Medications
Between 50 and 75% of people taking GLP-1 medications for weight loss stop within a year. One reason is cost, with out-of-pocket prices running into the hundreds of dollars monthly for those without coverage, and insurance coverage for weight loss use remains inconsistent across plans.
GLP-1 medications are also designed for lifelong use, developed to manage chronic conditions like type 2 diabetes or cardiovascular disease, and stopping them typically reverses whatever effect they had. That reality appears to matter to people before they start: interest in taking a prescription weight loss drug drops from 45% to 14% once people learn they will likely need to be on the medication for life.
Then there are the side effects, which are numerous and can be serious, including:
- Nausea, vomiting, and diarrhea, particularly in the early weeks of use
- Constipation and delayed gastric emptying
- Fatigue and dizziness
- Muscle loss
- Hair thinning
- Gallbladder problems, including gallstones, which can become life-threatening if untreated
- Pancreatitis, a serious inflammation of the pancreas that requires emergency care
- Thyroid concerns, particularly for anyone with a personal or family history of medullary thyroid cancer, for whom these medications are contraindicated
Side effects are among the most commonly cited reasons for stopping, with often the gastrointestinal symptoms alone are significant enough to make continuation difficult. For most, that is a reasonable response to a medication causing harm. For someone with an eating disorder, the calculus can be different. Continuing despite physical consequences is not a choice but a symptom.
Someone in the grip of an eating disorder may be among the least likely to stop a medication that is causing harm, precisely because tolerating harm in pursuit of thinness is how the disease operates. This raises a serious clinical question about whether people with these diagnoses face a compounded risk of staying on a medication that is making them sicker.
GLP-1s and Eating Disorder Risk
For people with restrictive eating disorders such as anorexia nervosa, appetite suppression does not treat the illness. It reinforces it. The cognitive distortions that sustain many eating disorders, such as the overvaluation of thinness and the fear of weight gain, are not addressed by a GLP-1, and in many cases they are strengthened by one. And those who are active in their eating disorder are not the only ones at risk.
Clinicians have documented patients in long-term remission whose eating disorders were fully reactivated after starting a GLP-1 medication, including one patient who relapsed so severely after years of recovery that hospitalization was required. The physiological side effects compound this: nausea and vomiting can reactivate somatic memories in people with a purging history, pulling them back toward patterns they had worked hard to leave behind.
For people with binge eating disorder, the picture requires equal care. GLP-1 medications may reduce binge episodes in the short term through appetite suppression, but they do not reach what drives binge eating. Binge eating disorder is frequently not a disorder of excess appetite, but rather something that is sustained by restriction and shame.
Restriction creates physiological deprivation, deprivation makes bingeing more likely, shame drives further restriction as well as isolation, and the cycle continues. A shot or a pill to quiet the food noise is a panacea—it may interrupt one part of that cycle, but leave its underlying structure entirely intact.
Weight Stigma and the Screening Gap
Underneath all of this is a healthcare system that has historically read larger bodies as problems to be solved rather than people to be screened. Eating disorder training is limited across the primary care, family practice, and endocrinology settings where most GLP-1 prescriptions originate, which means that the patients most likely to be harmed by these medications are also the least likely to be identified before a prescription is written.
A provider who sees a larger body and moves toward appetite suppression without asking about the person’s relationship with food, restriction, or body image is not practicing cautiously.
Navigating GLP-1 Medications with Eating Disorder-Informed Care
A team that includes a medical provider, a dietitian, and potentially a therapist with eating disorder training can help navigate the impact of GLP-1 medications for anyone who is on them, whether taken for weight loss or a chronic health condition. This can include making sure an individual remains properly nourished, working through the very real cultural pressures and weight bias that might drive or impact use, and if discontinuation is the right direction, how to do that safely.
GLP-1 medications have become one of the most talked-about medical developments in recent memory, and the speed of their cultural adoption has outpaced both research and clinical caution. They have also changed the conversation around how we interact with food, with the term “food noise” becoming increasingly common and used in place of hunger, cravings, and more.
These medications are expensive, often lifelong commitments, with side effects that are real—and for some people, serious. The risks for people with eating disorder histories are that much more significant, compounded by a healthcare system that has consistently failed to screen for disordered eating before prescribing medications that can trigger, worsen, or mask it.
At ‘Ai Pono, we recognize that there are many reasons someone may be taking GLP-1 medications. We take a nonjudgmental, collaborative approach that honors each client’s health, recovery goals, and individual context. If you are seeking treatment for an eating disorder while using or after having used a GLP-1 medication, we are here to help.
